Gromit Therapeutics

Is a clinical stage bio-pharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases across human and animal healthcare.

Medexplore Ventures has led the founding of the company in 2021, which has later executed an exclusive license agreement with the Icahn School of Medicine at Mount Sinai in New York, NY. The license agreement provides Gromit with access to a broad patent portfolio related to Sphingolipids metabolizing enzyme (SME) and its therapeutic application in senescence, inflammation and aging. This high value technology has been developed in the lab of Efrat Eliyahu, PhD, Assistant Professor of Genetics and Genomics Sciences at Icahn Mount Sinai, and is addressing acute and chronic inflammatory diseases and related conditions. The therapeutic protein is administered as gene therapy via using adeno-associated-virus mediated delivery.

Gromit Therapeutics is addressing the unmet needs in the field of aging and inflammation. The lead program is focused on Canine heath care in orthopedics and lung diseases. An ongoing clinical study enrolled over thirty patients to date, and collected initial evidence of safety and efficacy outcomes, with a follow-up period of over a year. The companion animals enrolled in the studies have exhausted all possible surgical or medical treatments and some were about to be euthanized before successfully treated with Gromit Therapeutics gene therapy. These findings will provide foundation for veterinary drug development and a number of IND applications for human indications, to be submitted within the year.